Long QT Syndrome News and Articles

Return to Library

Recent Long QT Syndrome News and Articles

• New Ion Channels Findings from Chinese Academy of Sciences Published
• Patent Issued for Isoquinolinone Potassium Channel Inhibitors
• Study Results from Toho University Provide New Insights into Pharmaceutical Research
• New Research on Cardiology Research from Mayo Clinic Summarized
• Study Data from University of Ottawa Update Understanding of Cardiology
• Researchers from University of Pennsylvania Publish Findings in Anesthesiology
• New Findings in Cardiology Research Described from University of Cape Town
• Reports from Umea University Advance Knowledge in Cardiovascular Diseases and Disorders
• Research on Pharmacology Published by Scientists at University of California

---

Research from University Medical Center Has Provided New Data on Schizophrenia

2013 JAN 7 (NewsRx) -- By a News Reporter-Staff News Editor at Mental Health Weekly Digest -- Researchers detail new data in Schizophrenia. According to news reporting from Hamburg, Germany, by NewsRx journalists, research stated, "Despite the progress in antipsychotic treatment, modern antipsychotic medication is still associated with side effects, reduced compliance, drug discontinuation and insufficient effects on negative and cognitive symptoms. Sertindole is an antipsychotic compound, with high affinity for dopamine D(2), serotonin 5-HT(2A), 5-HT(2C) and a(1)-adrenergic receptors, which has been reintroduced in the market after extended re-evaluation of its safety and risk-benefit profile."

The news correspondents obtained a quote from the research from University Medical Center, "AREAS COVERED: Sertindole's pharmacological profile, pharmacokinetics, neuophysiological properties, efficacy on positive, negative and cognitive symptoms and safety issues are covered in this article, based on a literature review from 1990 to 2012. EXPERT OPINION: Based on five double-blind, randomized, placebo-, haloperidol-or risperidone-controlled studies in patients with schizophrenia, sertindole shows a comparable efficacy with haloperidol and risperidone on positive symptoms, while the effect on negative symptoms seems to be superior. Sertindole is generally well tolerated, but is associated with a dose-related QTc interval prolongation (+22 ms). Risk factors for drug-induced arrhythmia, such as cardiac diseases, congenital long QT syndrome, prolongated QTc at baseline, etc. and drug interactions should be considered before prescribing sertindole. To minimize cardiovascular risk, regular ECG recording is required. Sertindole can be an important second-line option for the treatment of schizophrenia for patients intolerant to at least one other antipsychotic."

According to the news reporters, the research concluded: "Further comparison with other SGAs and investigations on subgroups (e.g., children, elderly, first-episode, treatment-refractory patients, etc.) are still needed for a precise understanding of the therapeutic benefits and its role in schizophrenia therapy."

For more information on this research see: Drug safety and efficacy evaluation of sertindole for schizophrenia. Expert Opinion On Drug Safety, 2012;11(6):1047-62.

Our news journalists report that additional information may be obtained by contacting E. Karamatskos, University Medical Center Hamburg-Eppendorf, Centre of Psychosocial Medicine, Dept. of Psychiatry and Psychotherapy, Martinistr 52, D-20246 Hamburg, Germany.

Keywords for this news article include: Antipsychotic, Europe, Hamburg, Germany, Psychiatry, Mental Health, Schizophrenia.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC